New anticoagulants in atrial fibrillation

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 6, 2009, Pages 574-585

  Harenberg, Job ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atrial fibrillation; Idraparinux; Oral anticoagulants; Oral factor Xa inhibitor; Oral thrombin inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; ASPARTATE AMINOTRANSFERASE; AVIDIN; BILIRUBIN; BIOTIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING INHIBITOR; CREATININE; CYTOCHROME P450 2C9; DABIGATRAN ETEXILATE; DU 176B; EPOXIDE; FONDAPARINUX; HIRUDIN; HIRULOG; IDRABIOTAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

AGING; ANTICOAGULATION; ARTERY EMBOLISM; BIOTINYLATION; BLEEDING; BLOOD LEVEL; BODY WEIGHT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FALL RISK; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; HYPERTENSION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KNEE ARTHROPLASTY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 70449389953     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1240018     Document Type: Review

References (61)

1. Hart R G., Pearce L A., Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 146 (12) 857-867
2. Go A S., Hylek E M., Henault L E. et al. Prevalence of diagnosed atrial fibrillation: national implications for management and stroke prevention: the ATRIA study. Circulation 1999 100 (suppl) 1-397
3. Hylek E M., Go A S., Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003 349 (11) 1019-1026
4. Albers G W., Diener H C., Frison L et al, SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005 293 (6) 690-698
5. Connolly S, Pogue J, Hart R et al, ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006 367 (9526) 1903-1912
6. Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006 60 (3) 258-264
7. Hirsh J, O'Donnell M, Eikelboom J W. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007 116 (5) 552-560
8. Singer D E., Albers G W., Dalen J E. et al, American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133 (6, suppl) 546S-592S
9. Johnson C E., Lim W K., Workman B S. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc 2005 53 (4) 655-659
10. van der Meer F J., Rosendaal F R., Vandenbroucke J P., Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993 153 (13) 1557-1562
11. Hutten B A., Lensing A W., Kraaijenhagen R A., Prins M H. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999 14 (4) 303-312
12. Pengo V, Legnani C, Noventa F, Palareti G, ISCOAT Study Group. (Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study. Thromb Haemost 2001 85 (3) 418-422
13. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 154 (13) 1449-1457
14. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996 156 (4) 409-416
15. Fang M C., Chang Y, Hylek E M. et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004 141 (10) 745-752
16. Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004 164 (18) 2044-2050
17. Schulman S, Beyth R J., Kearon C, Levine M N., American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133 (6, suppl) 257S-298S (Pubitemid 351892969)
18. Bates S M., Weitz J I. The status of new anticoagulants. Br J Haematol 2006 134 (1) 3-19
19. Eikelboom J W., Weitz J I. A replacement for warfarin: the search continues. Circulation 2007 116 (2) 131-133
20. Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic. Curr Top Med Chem 2005 5 (16) 1677-1695
21. Bauer K A. New anticoagulants. Curr Opin Hematol 2008 15 (5) 509-515
22. Turpie A GG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007 27 (6) 1238-1247
23. Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis. IDrugs 2004 7 (11) 1028-1034
24. Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss C. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008 64 (6) 555-563
25. Herbert J M., Hérault J P., Bernat A et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998 91 (11) 4197-4205
26. Bijsterveld N R., Vink R, van Aken B E. et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004 124 (5) 653-658
27. PERSIST investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004 2 (1) 47-53
28. Buller H R., Cohen A T., Davidson B et al, van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007 357 (11) 1094-1104
29. Buller H R., Cohen A T., Davidson B et al, van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007 357 (11) 1105-1112
30. Harenberg J, Vukojevic Y, Mikus G, Joerg I, Weiss C. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 2008 6 (5) 890-892
31. Savi P, Herault J P., Duchaussoy P et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008 6 (10) 1697-1706
32. Bousser M G., Bouthier J, Büller H R. et al, Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008 371 (9609) 315-321
33. Buller H R., Destors J M., Gallus A S. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin. [abstract 32] Blood 2008 112 18
34. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007 5 (Suppl 1) 60-64
35. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006 15 (8) 843-855
36. Agnelli G, Gallus A, Goldhaber S Z. et al, ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007 116 (2) 180-187
37. Buller H R., Lensing A W., Prins M H. et al, Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008 112 (6) 2242-2247
38. Pinto D J., Orwat M J., Koch S et al. Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007 50 (22) 5339-5356
39. Raghavan N, Frost C E., Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009 37 (1) 74-81
40. Wong P C., Crain E J., Xin B et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008 6 (5) 820-829
41. Frost C, Yu Z, Moore K. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 2007 5 (suppl 2) P-M-664
42. Buller H, Deitchman D, Prins M, Segers A, Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008 6 (8) 1313-1318
43. Iwatsuki Y, Shigenaga T, Moritani Y et al. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor [ASH Annual Meeting Abstracts, Abstract 911]. Blood 2006 108
44. Eriksson B I., Quinlan D J., Weitz J I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009 48 (1) 1-22
45. Eriksson B I., Turpie A GG, Lassen M R. et al, ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007 5 (8) 1660-1665
46. Zafar M U., Vorchheimer D A., Gaztanaga J et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007 98 (4) 883-888
47. Weitz J I., Connolly S TJ, Kunitada S. Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation [abstract 33]. Blood 2008
48. Linkins L A., Weitz J I. Pharmacology and clinical potential of direct thrombin inhibitors. Curr Pharm Des 2005 11 (30) 3877-3884
49. Weitz J I. Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 2007 5 (5, suppl 1) 65-67
50. Weitz J I., Büller H R. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 2002 105 (8) 1004-1011
51. Gustafsson D, Nyström J, Carlsson S et al. The direct thrombin inhibitor Melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001 101 (3) 171-181
52. Wolzt M, Sarich T S., Eriksson U G. Pharmacokinetics and pharmacodynamics of ximelagatran. Semin Vasc Med 2005 5 (3) 245-253
53. Diener H C., Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006 21 (4) 279-293
54. Boudes P F. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 2006 27 (5) 432-440
55. Lee W M., Larrey D, Olsson R et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005 28 (4) 351-370
56. Gurewich V. Ximelagatranpromises and concerns. JAMA 2005 293 (6) 736-739
57. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 64 (3) 292-303
58. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008 47 (1) 47-59
59. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 64 (3) 292-303
60. Ezekowitz M D., Reilly P A., Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007 100 (9) 1419-1426
61. Connolly S J., Ezekowitz M D., Salim Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 in press